CNVN 202

Drug Profile

CNVN 202

Alternative Names: Chol-fus1; Cholesterol-Fus1 liposome complex; DOTAP; DOTAP:Chol-fus1; DOTAP:chol-TUSC2; FUS1 cancer gene therapy; FUS1-DOTAP:cholesterol; INGN-401; Nanoparticle formulation FUS-1; Oncoprex; Oncoprex nanovesicles; TUSC2; TUSC2/FUS1

Latest Information Update: 10 Jan 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Introgen Therapeutics
  • Developer Genprex
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action FUS1 tumour suppressor gene transcription stimulants; FUS1 tumour suppressor protein stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-small cell lung cancer

Most Recent Events

  • 06 Jan 2017 Interim efficacy data from a phase II trial in Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Second-line therapy or greater) released by Genprex
  • 24 Aug 2016 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Second-line therapy or greater) in USA before August 2016 (IV) (NCT01455389)
  • 18 Jul 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top